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Purpose: Human papillomaviruses (HPV) may have a role in some breast cancers. 
The purpose of this study is to fill important gaps in the evidence. These gaps are: (i) 
confirmation of the presence of high risk for cancer HPVs in breast cancers, (ii) evidence 
of HPV infections in benign breast tissues prior to the development of HPV-positive 
breast cancer in the same patients, (iii) evidence that HPVs are biologically active and not 
harmless passengers in breast cancer.
Methods: RNA-seq data from The Cancer Genome Atlas (TCGA) was used to 
identify HPV RNA sequences in breast cancers. We also conducted a retrospective 
cohort study based on polymerase chain reaction (PCR) analyses to identify HPVs 
in archival specimens from Australian women with benign breast biopsies who later 
developed breast cancer. To assess whether HPVs in breast cancer were biologically 
active, the expression of the oncogenic protein HPV E7 was assessed by immunohis-
tochemistry (IHC).
results: Thirty (3.5%) low-risk and 20 (2.3%) high-risk HPV types were identified in 855 
breast cancers from the TCGA database. The high risk types were HPV 18 (48%), HPV 
113 (24%), HPV 16 (10%), HPV 52 (10%). Data from the PCR cohort study indicated 
that HPV type 18 was the most common type identified in breast cancer specimens 
(55% of 40 breast cancer specimens) followed by HPV 16 (13%). The same HPV type 
was identified in both the benign and subsequent breast cancer in 15 patients. HPV E7 
proteins were identified in 72% of benign breast specimens and 59% of invasive breast 
cancer specimens.
conclusion: There were four observations of particular interest: (i) confirmation by both 
NGS and PCR of the presence of high-risk HPV gene sequences in breast cancers, 
(ii) a correlation between high-risk HPV in benign breast specimens and subsequent 
HPV-positive breast cancer in the same patient, (iii) HPVs in breast cancer are likely to 
be biologically active (as shown by transcription of HPV DNA to RNA plus the expression 
of HPV E7 proteins), (iv) HPV oncogenic influences may occur early in the development 
of breast cancer.
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inTrODUcTiOn
High risk for cancer human papilloma viruses (HPVs) have been 
identified in breast cancers in 30 studies conducted in 17 countries 
and 4 continents (1, 2). HPV type 33 is the most prevalent (14%) 
but is mainly confined to Asian women, followed by HPV 18 (7%) 
and 16 (7%) (1, 2). In 10 case control studies, the prevalence of 
HPVs in breast cancers was significantly higher than in controls 
OR = 3.60 (1). Women with HPV-associated cervical neoplasia 
can later develop HPV-associated breast cancer (3, 4). However, 
several groups have not identified HPVs in breast cancer (5). All 
of the above studies have been based on polymerase chain reac-
tion techniques (PCR).
High-risk HPVs have been identified in breast cancers by Next 
Generation Sequencing – NGS (also known as massive parallel 
sequencing)1. These studies have been based on The Cancer 
Genome Atlas (TCGA) database of 855 breast cancers. They 
demonstrate that high-risk HPVs are present in <2% of breast 
cancers and at very low viral loads. Recently, 1.3% of the TCGA 
specimens have been shown to be contaminated with HPV type 
18 with the source probably HPV-positive HeLa laboratory cells 
(6). This contamination does not appear to affect the TCGA 
breast cancer specimens, which we have studied and reported in 
this current article (Cantalupo, 2015, personal communication). 
However, minor contamination cannot be excluded.
It is difficult to reconcile the data based on TCGA and ana-
lyzed by NGS, with the data based on Australian breast cancer 
specimens and analyzed by PCR. The TCGA data indicate a 2% 
prevalence of high-risk HPV-positive breast cancers compared to 
60% of Australian breast cancers in this current study. However, of 
this 60% only approximately 40% had observable protein expres-
sion. Other studies based on PCR, such as the Ohba et al. study 
of breast cancer in Singapore residents (7), and prior studies of 
Australian breast cancers, have identified high-risk HPVs in from 
25 to 100% of breast cancers (8, 9). The most likely explanation is 
the use of different viral identification techniques, namely, NGS 
as compared to PCR. NGS is a relatively new technique. Positive 
identification of HPV and other viruses is dependent on the 
recombination of fragmented gene sequences known as “reads.” 
There are no established conventions concerning the best length of 
the recombined “reads.” Therefore conclusions are in part, matters 
of opinion. While this may explain some of the different outcomes 
of NGS as compared to PCR, it is clear that the HPV viral load 
in breast cancer is extremely low as compared to cervical cancer.
While these data indicate that HPVs may have a possible role 
in some breast cancers, they may not have a major causal role. 
There are two reasons for this view: (i) in immunocompromised 
1  http://larssonlab.org/tcga-viruses/report_BRCA.php
patients (due to either human immunodeficiency infections or 
post organ transplantation therapy), there is no increased preva-
lence of breast cancer, which is in contrast to the two- to sixfold 
increased prevalence of HPV associated cervical and head and 
neck cancer in these patients (10), and (ii) the HPV viral load in 
breast cancer is extremely low (11, 12).
However, it is important to determine whether high-risk HPVs 
have a causal role in even a small proportion of breast cancers. In 
addition to the epidemiologically based evidence outlined above, 
there is substantial but incomplete evidence, which indicates a 
potential role for HPVs in breast cancer. This evidence includes: 
(i) HPVs immortalize and transform human mammary epithelial 
cells (13), (ii) HPVs are located in breast cancer cell nuclei (8), (iii) 
HPV E6 oncoprotein has been identified in breast cancers (8), (iv) 
high-risk HPVs have been identified in breast cancer cell cultures 
(8), (v) HPV-positive breast cancer is more common in young as 
compared to older women, an observation which is compatible 
with sexual transmission of HPV among sexually active younger 
women (14, 15), (vi) approximately 16% of normal Australian 
women are serologically HPV type 16 positive (16), and (vii) HPV-
positive koilocytes have been identified in breast cancers (17).
This evidence is incomplete. There is a need to determine (i) if 
high-risk HPVs are present in normal and benign breast tissues 
prior to the development of HPV-positive breast cancer and (ii) 
whether these HPVs are biologically active. These form the aims 
of this study.
MaTerials anD MeThODs
research approaches
The research approach to the first aim  –  identification of 
HPVs  –  was to use a range of different methods for the iden-
tification of HPVs. These methods included Next Generation 
Sequencing (NGS), in situ and standard PCR, and immunohis-
tochemistry. The approach to the second aim  –  identification 
of HPVs in benign non-malignant breast tissues prior to breast 
cancer – was conducted through a retrospective cohort study. The 
approach to the third aim – to determine the biological activity 
of HPVs in breast cancer – was to study HPV RNA sequences in 
breast cancers as indicators of transcription activity plus a study 
of HPV associated oncogenic protein expression.
Tcga next-generation sequencing Data 
and Bioinformatics analysis
Whole transcriptome sequencing data for 855 (USA) Breast 
 cancers were obtained through TCGA. Sequencing has been 
done using Illumina (Solexa, GAII) or SOLiDTM technology. 
A  detailed description of the TCGA data can be found on 
the  following TCGA websites: http://cancergenome.nih.gov/, 
https://tcga-data.nci.nih.gov/tcga/. Transcriptome data (BAM 
files) generated by TCGA were analyzed in an automated fashion 
on a computational cluster hosted by the High-Performance 
Computing core at the Center for Computational Science, 
University of Miami2. All non-viral sequences were subtracted 
2 http://ccs.miami.edu/
Abbreviations: APOBEC3B, apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3B; CIN, cervical intraepithelial neoplasia; EBV, Epstein–Barr 
virus; ER, estrogen receptors; HER 2 (also known as ErbB-2), human epidermal 
growth factor receptor 2 protein; HPV, human papilloma virus; HPV E7, human 
papilloma virus E7 protein; IHC, immunohistochemistry; NGS, next generation 
sequencing; PCR, polymerase chain reaction; PR, progesterone receptors; r, cor-
relation co-efficient; TCGA, the cancer genome atlas.
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from NGS data as described in Salyakina and Tsinoremas (18). 
Reference genomes for all known HPV types obtained from PaVE 
database3 were used for HPV screening. Even the single short 
read 48 nt or longer aligning to the viral reference was considered 
as successful detection, if following BLAST analysis versus the 
NCBI nucleotide collection confirmed sequence similarity with 
the target over 98%. Sequences aligning to multiple organisms, 
known artificial (vector) sequences, or low complexity sequences 
were considered false positive and removed.
The outcomes for HPV 18 were compared to the outcomes 
of the Larsson lab for the same TCGA breast cancer specimens.
APOBEC gene family mutations and expression data for TCGA 
cohort were available for 850 out of 855 analyzed samples from 
http://www.cbioportal.org. The Fisher exact test was employed 
to test possible association of HPV status with APOBEC genes 
expression or mutations.
Clinical data was available for 836 out of 855 patients from the 
TCGA portal.
These analyses were conducted by Daria Salyakina at the 
Center for Computational Science, University of Miami, Coral 
Gables, FL, USA.
retrospective cohort study
We conducted a retrospective cohort study to identify HPV 
sequences in benign breast biopsy tissues in women who later 
developed HPV-positive breast cancer. This is a practical and 
low-cost method of achieving sound outcomes. If the HPV DNA 
was of the same type and sequence in both the prior benign 
breast tissues as in the subsequent breast cancer tissues from the 
same patient this potentially provides evidence of prior HPV 
breast infection. All the specimens were from women residing 
in Australia. We reviewed approximately 4,000 pathology reports 
of breast cancer and identified 41 patients who had benign breast 
biopsies 1–11 years prior to developing breast cancer. The pathol-
ogy reports of associated archival formalin fixed specimens from 
these patients were identified and collected from an Australian 
pathology service (Douglas Hanly Moir Pathology). The average 
age of the patients with benign breast conditions was 50.5 years 
and subsequent cancer 56.1 years.
We used normal breast specimens from 21 patients who had 
cosmetic breast surgery as a comparative group. The average age 
of these donors was 35.7 years. These patients were much younger 
than the patients who developed breast cancer, and therefore are 
not an exact control group. None of these patients had developed 
breast cancer 10 years after the initial surgery.
identification of hPV gene sequences by 
Polymerase chain reaction
In  situ PCR, semi-nested PCR, and real-time PCR were used 
for the detection of HPV. All PCR products were sequenced 
to help identify any contamination. Although in  situ PCR can 
produce false positive outcomes, use of this method can add to 
the validity of results based on semi-nested and real time PCR. 
3 http://pave.niaid.nih.gov/
The detailed methods are presented in Supplementary Materials 
and Methods.
Preparation of Genomic DNA
For standard and real-time PCR, the methods were as described 
in Steinau et al. (19). The primers used were β-actin 5′ forward 
(5′-CTTCTGCCGTTTTCCGTAGG-3′) and β-actin 3′ reverse 
(5′-TGGGATGGGGAGTCTGTTCA-3′).
Standard PCR
The primers for semi-nested PCR My11 
(5′-GCACAGGGYCAYAAYAATGG-3′) to modified GP6 
(5′-AATCATATTCCTCMMCATGTC-3′). The second round 
was Gp5+ (5′-TATTTGTTACTGTKGTWGATAC-3′) to Gp6+. 
These primers were degenerate for HPV16 and 18, but were also 
capable of bringing up types 3, 11, 12, 45, 58, 73, and 75.
Real-Time PCR
The HPV L1 gene in gDNA samples was amplified using a real-
time PCR machine (Rotor Gene Q, QIAGEN).
Sequencing the PCR Products and Identification of HPV Types
The HPV PCR products from GP5 to Gp6 were sequenced to 
determine the HPV type. The HPV genotypes were identified by 
BLAST via the US National Center for Biotechnology Information.
In situ PCR
These analyses were conducted as described in Heng et al. (8). 
In  situ PCR is less susceptible to contamination and has the 
important advantage of localizing the specific genetic material at 
the cellular level.
The identification by PCR of HPV in benign non-malignant 
breast or breast cancer specimens was considered as positive 
if two or more of the following outcomes in the same speci-
men were observed: (i) HPV DNA sequences identified by 
standard PCR and/or real time PCR, (ii) HPV positive in situ 
PCR.
Confirmatory PCR Studies
DNA extracts from six selected (for positive HPV) benign and 
breast cancer specimens were independently analyzed by the 
Antonsson group at the QIMR Berghofer Medical Research 
Institute, Brisbane, for the presence of HPV DNA using their 
previously published methods (20).
hPV Biological activity
An assessment of HPV biological and oncogenic activity was 
conducted by (i) the identification of HPV RNA sequences, 
which are an indication of HPV transcription activity (ii) the 
identification of HPV E7 proteins, (iii) the high expression of 
p16 protein, (iv) high expression of ER, and (v) inhibition of p53 
protein expression.
Antibodies that are specific for HPV E7 proteins, have recently 
been developed (21). These antibodies (Cervimax) were used 
in this study. The specificity of these antibodies has been dem-
onstrated experimentally and by epidemiological studies (21). 
TaBle 1 | hPV types in Tcga breast cancers – next generation 
sequencing.
high-risk hPVs n = 20
HPV 16 – 2 (10%) HPV E1, E2, E6, E7, and L1 identified
HPV 18 – 10 (50%) HPV E1, E6, and E7 identified
HPV 31 – 1 (5%) HPV E7 identified
HPV 35 – 1 (5%) HPV E7 identified
HPV 52 – 2 (10%) HPV E2, E4, E5, and E7 identified
low-risk hPVs n = 30
HPV 4 – 3 (10%)
HPV 17 – 3 (10%)
HPV 22 – 2 (7%)
HPV 38 – 2 (7%)
HPV 49 – 3 (10%)
HPV 65 – 2 (7%)
HPV 113 – 4 (20%) HPV L1, L2, E7 identified
HPVs 1, 4, 5, 10, 15, 17, 19, 22, 23, 24, 38, 49, 63, 65, 80, 93, 104, 110, 
124, 132, 137 – one identification each.
Low and high risk types of HPV sequences were identified in 50 of 855 TCGA breast 
cancers. E5, E6, and E7 oncogenes were identified.
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The  HPV E7 antibody reacts with a wide range of HPV types 
including high risk for cancer HPV 16 and 18. HPV E7 antibodies 
have not been previously used on breast tissues.
p16
p16 contributes to regulation of the cell cycle. There is substantial 
evidence that indicates that p16 expression is associated with 
HPV biological activity (22). High expression of p16 as a surro-
gate for HPV E7 activity is a sound indication of transcriptionally 
active HPV (23). In breast tissues, negative or low expression of 
p16 is present in normal ductal epithelial tissues with a progres-
sive increase of p16 expression in benign and malignant breast 
lesions (24–26). The situation is complicated by Epstein–Barr 
virus (EBV), which blocks the expression of p16 (27).
p53
The inhibition of expression of the cell death related p53 protein 
by HPV E6 protein is a well-documented mechanism for HPV 
oncogenesis. p53 expression is inhibited in HPV 16-positive 
breast cancer (28).
Estrogen Recptor
Estrogens have an essential role in breast cancer and high ER 
expression is a feature of most breast cancers (29). Recently, high 
ER expression has been associated with HPV-positive breast 
cancers (30).
HER 2 (ErbB-2)
The HER 2 receptor co-operates with HPV E6 and E7 oncopro-
teins in breast oncogenesis (31).
immunohistochemistry
Standard manual IHC methods were used with the omission of 
the antigen retrieval step for the identification of HPV E7 pro-
tein expression. The antibodies were anti-HPV E7 monoclonal 
“Cervimax”  –  Valdospan GmbH, Austria. Positive controls for 
the E7 antibody were the Hela (HPV18) cell line and cervical 
tissues that were positive by PCR and sequencing.
Immunohistochemistry for estrogen receptor (ER), pro-
gesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER 2) were previously performed as part of the 
standard assessment of breast cancer specimens. For benign 
breast specimens, the same assessments were conducted as part 
of this current project.
ER, PR, p16, and p53 proteins are expressed in cell nuclei. HER 2 
protein is expressed in cell cytoplasm and membranes. HPV types 
16 and 18 E6 protein is expressed in both cell nuclei and cytoplasm. 
Anatomical pathologists from Douglass Hanly Moir – Pathology 
conducted the routine assessment of ER, PR, and HER in breast 
cancer specimens. Two independent observers (James S. Lawson 
and Wendy K. Glenn) used the same methods for the assessment 
of ER, PR, and HER in the benign breast specimens. The staining 
of breast tissues during immunohistochemistry procedures is het-
erogenous with staining frequently confined to only part of a tissue 
section. The assessments were based on those tissue sections with 
positive staining cells. The outcomes were assessed by the intensity 
of staining on a scale of 0 and 1–3. Positive (HPV-positive cervical 
cancer specimen) and negative (antibody omitted) controls were 
used for each batch of specimens.
In breast cancer specimens, IHC staining for p16 appears to 
differ from the patterns commonly seen in cervical neoplasia. 
p16 expression in both non-invasive and invasive breast cancer 
specimens are most commonly seen in clusters of cancer cells 
with no staining in other parts of the cancer specimen (23). For 
this reason, we have adopted the same methods of assessment 
as outlined above for ER and PR but confined to assessments of 
percentages of positive and intensity of staining cancer cells in 
the clusters. We have adopted the same approach to assessment 
of p53, which also commonly stains in clusters in breast cancer 
specimens.
statistics
Associations between HPV identification and various breast 
specimens were tested for correlations using the SPSS statistical 
package. The tests were all two-sided, and statistical significance 
was defined as p ≤  0.05. The numbers in this study are small. 
Accordingly, it is necessary to be cautious despite some of the 
results reaching statistical significance. The specific statistical 
tests used are listed with the different results sections.
resUlTs
identification of hPV gene sequences in 
the Tcga Breast cancers cohort
Whole transcriptome data identified 30 (3.5%) tumors with low-
risk and 20 (2.3%) with high-risk HPV types in 855 breast cancers 
from the TCGA cohort (Table S1 in Supplementary Material). 
The high risk types that were identified in the TCGA cohort were 
HPV 18 (50%), HPV 113 (20%), HPV 16 (10%), HPV 52 (10%) 
plus one identification of HPVs 31 and 35 (5% each) (Table 1). 
Three specimens had two HPV types.
As outlined in the Section “Introduction” of this report, 1.3% 
of the TCGA specimens have been shown to be contaminated 
with HPV type 18. The source of contamination was probably 
FigUre 1 | hPV type 18 e6 and e7 rna gene sequence identified in an invasive breast cancer specimen by next generation sequencing. Invasive 
breast cancer specimen 36 TCGAAR-A24P-01A-11R-A169-07 (see Table S1 in Supplementary Material) sequence compared to reference HPV 18 KC470228. E6 
gene sequences reference 105-581, E7 590-907, E1 914-2887. The two point mutations at reference 484 and 490 have been observed in reference HPV 18 
KC470209.1.
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by NGS in breast cancer are shown in Figure 1. The homology 
between the identified viral and reference sequences was greater 
than 95%. These HPV RNA sequences indicate that this virus has 
the capacity to express HPV E6 and E7 proteins, which interact 
with p53 and Rb to cause malignant transformation.
Associations between HPV and APOBEC could not be 
detected in the TCGA cohort with respect to either mutations or 
high/low APOBEC expression levels (p > 0.05).
identification by Pcr of hPV gene 
sequences in australian Benign and 
subsequent Breast cancers
As shown in Table 2 and Table S2 in Supplementary Material, 
fifteen (65%) of the HPV-positive specimens were of the 
same type in both the benign and subsequent breast cancer 
(p = 0.001).
Consistent variations in the HPV sequences of both the 
benign and subsequent IDC breast cancers in the same patients is 
suggestive that the same HPV infection is involved in both sets of 
breast tissues. HPV 18 sequences were identified in five of seven 
ductal carcinoma in situ (DCIS) breast cancer specimens. HPV 
18 was identified in three of seven benign and subsequent DCIS 
HPV-positive HeLa laboratory cells (6). This contamination does 
not appear to affect the TCGA breast cancer specimens that we 
have studied and report in this current article (Cantalupo, 2015, 
personal communication). However, minor contamination can-
not be excluded.
When considered together, the HPV nucleotides that have 
been identified in the 50 breast cancer specimens range from 
position 109 to 6589 on the HPV 18 complete genome, which 
has approximately 7,800 nt.
The majority of breast tumors had extremely low levels of 
viral expression with one or two short reads identified result-
ing in 50–100 nt long unique HPV fragments. Only four of the 
tumors showed longer continuous sequences of 300 nt or more. 
All identified HPV sequences had high and specific homology 
to reference HPV genomes. Short reads were randomly spread 
over thousands of nucleotides of the viral genome with large gaps 
between them due to the low viral load. An example of sequence 
reads can be seen in Figure 1.
The outcomes for HPV type 18 were identical to those of the 
Larsson lab.
HPV E7 gene sequences were identified in each of the high-
risk HPV groups of breast cancers. HPV E7 oncoproteins are 
involved in oncogenesis. HPV E6 and E7 protein gene sequences 
FigUre 2 | hPV type 18 Dna sequences in benign breast and subsequent breast cancer. There are identical sequence variations of a PCR product Gp5+ 
to Gp6+ in both the benign and later breast cancer in patient 21. (The sequence has been abbreviated to include the differences). This indicates it is the same virus 
and differs from the reference sequences based on HeLa cervical cell culture.
TaBle 2 | high risk hPV sequences in benign breast and 
subsequent invasive ductal carcinoma (iDc) breast cancer specimens 
in the same patients.
hPV 
sequences
same hPV 
type: benign/
cancer
nil hPV benign 
hPV- positive 
cancer
hPV-positive 
benign nil hPV 
cancer
HPV 16 1 1
HPV 16/18 2
HPV 18 13 3 3
HPV 58 1 1
Nil HPV 10
Fifteen (65%) of the HPV-positive specimens were of the same type in both the benign 
and subsequent breast cancer (p = 0.001).
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specimens. The PCR products that were detected and sequenced 
are from the L1 region of the HPV genome.
HPV type 18 was the most common type identified in breast 
cancer specimens (55% of 40 IDC and DCIS breast cancer speci-
mens) followed by HPV 16 (13%) and uncommonly HPV high-risk 
types 45, 58, and 73. Low-risk HPV types 3, 78, and 124 plus three 
different new HPV types were also identified. There were mixed 
HPV types in both prior benign and later breast cancer specimens. 
HPV viruses were not identified in 7 of 40 (17.5%) of sets of both 
benign and subsequent breast cancer specimens. Sequences 
from one benign and three invasive breast cancer specimens 
contained novel HPV sequences whose identity was the same as 
that reported from a Sydney renal transplant patient (AF019978).
The details of these findings are shown in Table S2 in 
Supplementary Material.
HPV type 18 DNA sequences in benign and subsequent breast 
cancer in a typical patient are shown in Figure 2. HPV sequences in 
a breast DCIS specimen is shown in Figure 3. As demonstrated in 
Figure 2, there are identical sequence variations of a PCR product 
Gp5+ to Gp6+ in both the benign and later breast cancer. These 
variations differ from the reference sequences based on HeLa cer-
vical cell cultures and suggest that HPV infection of benign breast 
tissues has later become the same HPV virus-positive invasive 
breast cancer. In other HPV 18-positive sets of benign and later 
breast cancers, the sequence patterns were identical in the benign 
breast, subsequent breast cancer, and reference HeLa sequences.
An HPV 18-positive mixed DCIS and invasive ductal carci-
noma of the breast identified by in situ PCR is shown in Figure 3. 
This image is typical of other images of invasive and non-invasive 
breast cancers identified by in situ PCR.
The identification of different, new, and novel HPV types in 
both the benign and breast cancer specimens indicates that false 
positive outcomes due to contamination during PCR analyses are 
unlikely.
The difference in prevalence of HPV sequences between 
normal breast and benign breast is significant (p =  0.001) and 
between normal breast and breast cancer is significant (p = 0.001) 
(Table 3).
confirmation of Data Based on Pcr
DNA extracts from six HPV-positive benign and breast cancer 
(extracted and analyzed at the University of New South Wales 
laboratories) patients were independently analyzed at the 
Antonsson laboratories in Brisbane, QLD, Australia. HPV types 
16 and 18 were identified in 2 of 6 specimens. The identification 
of different HPV types indicates that contamination is unlikely.
indicators of hPV Biological activity and 
Oncogenic influences
Identification of RNA by Next-Generation 
Sequencing
The identification of DNA viruses in cancer tissues by NGS 
involves recognition of RNAs. DNA viruses must be biologically 
active to transcribe into RNAs. Therefore, the outcomes of NGS 
in this investigation provide evidence that the high-risk HPVs 
identified are biologically active. In addition, the identification 
of HPV E6 and E7 genes in these high-risk HPV sequences is an 
indication that they are capable of expressing HPV E6 and E7 
oncoproteins.
Immunohistochemistry for HPV E7
The data are shown in Table  4 and in detail in Table S2 in 
Supplementary Material. The prevalence of HPV E7-positive 
protein expression is similar in both HPV-positive and HPV-
negative benign breast specimens. The prevalence of HPV 
E7-positive protein expression is significantly higher in HPV 
DNA sequence-positive as compared to HPVsequence-negative 
breast cancer specimens (Pearson chi-square p = 0.007).
In nine sets of specimens, there was strong HPV E7 expres-
sion in the benign breast specimens but little or no HPV E7 
staining in the subsequent breast cancer that developed later in 
the same patient. This is illustrated in Patient A in Figure 4 in 
which there is high HPV E7 protein expression in the cell nuclei 
of the benign breast specimen but no expression in the nuclei of 
the subsequent breast cancer specimens. This pattern was not 
observed in four sets of specimens, in which the HPV E7 protein 
expression was higher in the cancer than the prior benign breast 
cell nuclei. This different pattern of HPV E7 protein expression 
TaBle 4 | hPV e7 protein expression in high risk hPV-positive and 
-negative benign breast and invasive ductal carcinoma (iDc) and ductal 
carcinoma in situ (Dcis) breast cancer.
hPV Dna 
sequences 
(Pcr)
hPV e7 positive 
(immunohistochemistry)
hPV e7 negative 
(immunohistochemistry)
Benign breast
HPV positive 
n = 20
13 (65%) 7 (35%)
HPV negative 
n = 11
8 (73%) 3 (27%)
iDc and dcis breast cancer
HPV positive 
n = 21
16 (76%) 5 (24%)
HPV negative 
n = 9
2 (22%) 7 (78%)
The prevalence of HPV E7-positive protein expression is similar in both HPV-positive 
and HPV-negative benign breast specimens.
The prevalence of HPV E7-positive protein expression is significantly higher in HPV 
DNA sequence positive as compared to HPV-negative breast cancer specimens 
(Pearson chi-square p = 0.007).
TaBle 3 | identification by Pcr of high risk for cancer hPVs in normal 
breast (source cosmetic surgery), benign breast and breast cancer 
(same patients with prior benign breast and subsequent breast cancer).
Tissue type high risk hPV sequences
Normal breast n = 21 6 (29%)
Benign breast n = 40 22 (55%)
Breast cancer n = 40 27 (66%)
The difference in prevalence of HPV sequences between normal breast and benign 
breast is significant (p = 0.001) and between normal breast and breast cancer is 
significant (p = 0.001).
FigUre 3 | hPV by in situ Pcr in a breast ductal carcinoma in situ specimen. (a) HPV; (B) Negative (no primers) control.
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is shown in Patient B in Figure  4. The implication is that the 
oncogenic influence of HPVs may be early in step by step onco-
genesis in some patients. This will be considered in detail in the 
Section “Discussion.” The positive control for HPV E7 protein 
expression – HPV type 18 cervical intraepithelial neoplasia (CIN 
1), is shown in Figure 5.
There were no correlations between p16, p53, ER, PR, and 
HER2 protein expression in benign breast biopsy tissues and sub-
sequent HPV-positive breast cancer (Table S2 in Supplementary 
Material). There were no correlations between the identification 
of HPVs and the presence of proliferative breast epithelial cells 
in benign breast biopsy tissues.
p16 proteins were highly expressed (2 or 3 on a scale of 0–3 
staining intensity) in 12 benign and 11 invasive breast cancers 
in which high-risk HPVs had been identified (Table S2 in 
Supplementary Material). However, similarly high p16 expres-
sion was present in four benign and five invasive breast cancers 
in which HPV sequences were not identified.
Estrogen receptor protein expression
The expression of ER was very high in normal, benign, and 
subsequent breast cancer (Table S2 in Supplementary Material) 
whether or not HPV was identified. Therefore, HPV influences 
cannot be implied from these data.
HER2 protein expression
There was no correlation between the identification of HPV 
sequences and HER2 protein expression in either benign or later 
breast cancer.
left or right Breast cancer Following 
Prior Benign Breast conditions
In the same patients, 49% of the breast cancers developed in 
the same side as the benign breast condition and 51% devel-
oped in the opposite side breast. There was no association 
between HPV-positive breast cancers and whether the side of 
breast was the same as the prior HPV-positive benign condi-
tion. These observations suggest that if HPVs are oncogenic 
in breast cancer, the prior HPV infection and oncogenic 
influences may affect both breasts but only one develops 
breast cancer.
DiscUssiOn
These investigations indicate (i) data based on the TCGA by 
Next-Generation Sequencing (NGS) confirms the identification 
of high-risk HPVs in approximately 2% of breast cancers, (ii) that 
high-risk HPV sequences of the same type identified by PCR are 
present in 37% of benign non-malignant breast and subsequent 
non-invasive and invasive breast cancers in the same Australian 
FigUre 5 | hPV e7 protein expression identified in hPV type 18 
positive cervical intraepithelial neoplasia (cin 1). This is a positive 
control for Cervimax antibodies used in the immunohistochemistry analyses.
FigUre 4 | hPV e7 protein expression in hPV 18-positive benign and subsequent hPV 18-positive breast cancer demonstrated by 
immunohistochemistry. Patient A. Benign breast specimen from a patient at age 33 years and subsequent invasive breast cancer in the same patient aged 44 
years. HPV E7 protein brown staining is positive, blue staining is negative. There is strong HPV E7 protein expression in the nuclei of benign specimen. There is no 
HPV E7 protein expression in the subsequent invasive breast cancer specimen from the same patient. These observations are compatible with HPV having a role 
early in breast oncogenesis. Patient B. Benign breast specimen from a patient at age 53 and subsequent breast cancer in the same patient aged 62 years. There is 
strong HPV E7 protein staining in both the benign and subsequent breast cancer.
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patients, and (iii) high-risk HPVs in breast cancer are biologi-
cally active as indicated by HPV E7 protein expression and the 
transcription of HPV DNA to RNA. In addition, the observation 
that HPV E7 protein may be highly expressed in the nuclei of 
benign breast cells but not expressed in the nuclei of subsequent 
breast cancer cells suggests HPV biological activity in breast 
cancer may be an early phenomena. This differs from cervical 
cancer, which usually requires the continuing presence of active 
HPVs for oncogenic progression.
In this study, HPV type 18 was the most frequently identified 
type. In each of the previous studies of HPV in Australian breast 
and prostate cancers, HPV type 18 has been the most common 
type (8, 9, 32). Types of high-risk HPVs vary in different popula-
tions. For example, HPV type 58 is common in Chinese breast 
cancers and HPV types 33 and 35 are the most common in Syrian 
breast cancers (33). HPV type 18 was the most common type 
identified by the Larsson Lab in the TCGA breast cancer data 
bank, which contains predominently US breast cancers. HPV 
type 16 was the most common type recently identified in breast 
cancers in Egyptian patients (34).
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Validity of the Findings
The use of a range of techniques, namely, NGS, in  situ PCR, 
nested PCR, real-time PCR, and immunohistochemistry, 
substantially adds to the validity to the outcomes. However, 
the identification of HPVs by NGS is much lower than their 
identification by PCR techniques. The high number of short 
“reads” by NGS can be regarded as an indication of possible false 
positives; however, the very high specificity and homology to 
HPV reference sequences suggests the outcomes are valid. The 
findings based on NGS confirm the extremely low HPV viral 
load in breast cancer.
The finding by both NGS and PCR of a variety of HPV types, 
suggests these HPV sequences were derived from patient samples 
and not contaminants. With respect to outcomes, based on NGS, 
there does not appear to be contamination (Cantalupo, 2015, 
personal communication). However, as previously indicated, 
minor contamination cannot be excluded. The identical identi-
fication by NGS of HPV 18 in the same TCGA breast cancers 
by the Larsson lab and in this current study adds to the validity 
of the NGS results. The outcomes of the investigations based on 
PCR are in agreement with the recent results of Ohba et al (7) 
who identified high-risk HPVs in 20 to 100% of breast cancers in 
different ethnic groups in Singapore. They used novel DNA chip 
technology for the identification of HPVs.
The HPV E7 gene sequences identified by NGS add validity to 
the outcomes based on immunohistochemistry.
identification of high-risk hPVs in Benign 
non-Malignant Breast and subsequent 
Breast cancer
The much higher prevalence of HPV sequences in both the benign 
non-malignant breast and later breast cancer as compared with 
their prevalence in normal breast tissues from cosmetic surgery is 
striking. It is particularly noteworthy that HPV type 18 sequences 
with identical variations from the HeLa reference sequence were 
identified in benign breast tissues and 1–11 years later in breast 
cancer in the same patients. This suggests that it is probably the 
same virus in both the benign and subsequent breast cancer that 
developed later in the same patient. This finding adds to the Hill 
(35) criteria for causation.
HPV type 18 is the most common HPV type in breast cancer 
among Australian women (8, 9). HPV type 18 is also tropic to 
glandular cervical epithelial cells (36). The high (55%) proportion 
of HPV type 18 identified by PCR is very similar to the propor-
tion of HPV type 18 identified in adenocarcinoma of the cervix 
(36). It is therefore of considerable interest that HPV 18 was by 
far the most common HPV type identified by NGS in the TCGA 
breast cancers.
conflicting Data
It is difficult to reconcile the data based on TCGA and analyzed by 
NGS, with the data based on Australian breast cancer specimens 
and analyzed by PCR. The TCGA data indicates a 2% prevalence 
of high-risk HPV-positive breast cancers compared to 60% of 
Australian breast cancers in this current study. Other studies 
based on PCR, such as the Ohba et al. study of breast cancer in 
Singapore residents (7), and prior studies of Australian breast 
cancers, have identified high-risk HPVs in from 25 to 100% of 
breast cancers (8, 9). The most likely explanation is the use of dif-
ferent viral identification techniques, namely, NGS as compared 
to PCR. An additional explanation is that only about 40% of the 
60% of Australian breast cancers that were positive for high-risk 
HPV sequences had observable HPV protein expression. As the 
TCGA data is based on protein expression, this may explain part 
of those differences.
However, this does not explain the two- to six-fold higher 
prevalence of other HPV associated cancers, such as cervical 
cancer, in immunocompromised patients, as compared to 
immunocompromised patients with breast cancer (10). There 
are several possible explanations. One, HPVs may be present in 
breast cancers but are mostly not oncogenic, and are therefore 
unaffected by immunosuppression. Two, the oncogenic mecha-
nisms of HPVs in breast cancer may differ from those in cervical 
cancer and may not be affected by immunosuppression. In our 
view, the second explanation is the most likely.
The mechanisms of HPV oncogenesis in cervical cancer are 
well established and include the influences of HPV E6 and E7 
oncoproteins, which work in concert to disrupt cell-cycle regula-
tion, inhibit apoptosis, and stimulate cell cycle progression by 
binding and inhibiting the p53 and p110RB tumor suppressor 
genes (28). In most instances, continued presence of HPV is 
required for cervical oncogenesis. In addition, HPV E5 and E6 
act early in transformation (before integration) and are known to 
disrupt cytokeratin causing perinuclear cytoplasmic clearing and 
nuclear enlargement, which leads to the appearance of koilocytes 
(cells with halos surrounding the nuclei) (28).
There is experimental evidence that indicates there are differ-
ent HPV oncogenic mechanisms in breast cancer as compared 
to cervical cancer. Much of this evidence has been developed by 
Ohba et al. in Singapore (7). They have demonstrated (i) that breast 
cancer cells with high ER protein are significantly correlated with 
high HPV infections (ii) that HPVs appear to activate APOBEC3B 
enzymes leading to genomic instability – abnormal APOBEC3B 
protein expression has been associated with increased breast 
cancer risk (37, 38). These oncogenic influences occur in the early 
stages of multi-step, multi-factorial breast carcinogenesis.
In this current study, we have observed there may be higher 
levels of HPV E7 protein expression in the nuclei of benign breast 
glandular cells as compared to HPV E7 expression in the nuclei of 
subsequent breast cancer cells in the same patients. This observa-
tion supports the hypothesis that HPVs may be involved in the 
early stages of breast oncogenesis. This may be the HPV “hit and 
run” phenomenon previously described by others (39).
Overall, this evidence offers a plausible explanation for the 
lack of influence of immunosuppression in HPV associated breast 
cancer.
indicators of hPV Biological activity and 
Oncogenic influences
The outcomes of NGS in TCGA data in this investigation 
provide suggestive evidence that the high-risk HPVs identified 
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are biologically active. This is demonstrated by the recognition 
of HPV RNAs by NGS. This is because HPVs are DNA viruses 
that generate RNA transcripts for the expression of oncogenic 
proteins.
There was a significant correlation (r =  0.603, p =  0.004) 
between positive and negative HPV sequence identification and 
HPV E7 protein expression in normal (cosmetic surgery) breast 
tissues. The implication is that HPV E7 protein is a likely indica-
tor of HPV biological activity in breast tissues. However, 10 years 
later, none of the women who had HPV-positive normal breast 
tissues had developed breast cancer. Therefore, the identification 
of HPV sequences and HPV E7 protein expression in benign 
breast tissues does not necessarily lead to subsequent breast 
cancer.
The inhibited expression of p53 protein in benign non-
malignant breast and breast cancer observed in this study 
parallels the prior observation by Hennig et al (3). The inhi-
bition of expression of the cell death related p53 protein by 
HPV E6 protein is a well-documented mechanism for HPV 
oncogenesis (28).
The role of p16 in breast cancer is not clear. In this current 
study, there were no significant differences in p16 protein expres-
sion as assessed by IHC between normal, benign, and malignant 
breast tissues. In addition, there were no significant correlations 
between high p16 protein expression and triple negative breast 
cancer as has been observed in other studies (40, 41). High p16 
protein expression has been associated with HPV infections in 
breast, cervical, and other cancers (40, 41). However, in these and 
other studies of p16 expression in breast cancer, normal breast 
controls were not used, and therefore is not possible draw any 
conclusions from our current data.
hPV Transmission
The mode of transmission of HPV to the breast is not known. 
However, it is possible that HPVs are transmitted to the genital 
tract during sexual activities and later transmitted by white blood 
cells throughout the body. including the breasts. This hypothesis 
is based on the young age of women with HPV-positive breast 
cancer. These young women are sexually active and have a high 
incidence of HPV cervical infections (42). In addition, there have 
been repeated identification of high-risk HPVs in white blood 
cells (43).
Breast cancer is hormone Dependent
The presence of a hormone influenced virus in breast cancers 
is of special interest. The levels of ER expression in normal, 
benign, and breast cancer specimens in this study were very 
high. High ER expression in association with HPV-related 
breast cancer was also observed by Ohba (7). Estrogens syner-
gize with high-risk HPV E6 and E7 oncogenes to cause human 
cervical cancer (44). In addition, the regulatory region of 
HPV 16 genomic DNA contains sequences that are responsive 
to glucocorticoid hormones. The HPV18 regulatory region 
contains one functional GRE sequence that interacts with the 
glucocorticoid receptor and confers hormonal activation to 
HPV18 promoter (45).
Benign Breast Disease as Precancerous
These data indicate the marked differences between normal 
breast and benign breast tissues. These differences include the 
significantly higher prevalence of HPV sequences and prolifera-
tion of epithelial cells in benign as compared to normal breast 
tissues. In addition, there is a significant correlation between 
benign and later breast cancer in the same patient for the 
identification of HPV gene sequences and abnormal biomarker 
expression, including HPV E7 protein expression. While it is 
well documented that “benign” breast hyperplasia (glandular 
cell proliferation) leads to a fourfold increased risk of breast 
cancer, the observations in this current study, suggest that non-
proliferative benign breast disease may also be precancerous 
(46, 47).
left or right Breast cancer Following 
Prior Benign Breast conditions
The observation that there was no association between the side 
of HPV-positive benign breast conditions and the side of later 
HPV-positive breast cancer is of considerable interest. It may be 
that prior HPV infection and oncogenic influences may affect 
both breasts but only one develops breast cancer. However, there 
is no evidence from this current study to support this notion. 
The development of breast cancer in both breasts either at the 
same or at different times occurs in women with and without a 
genetic predisposition to develop breast cancer (48). The risk of 
bilateral breast cancer at different times is higher among young 
women (48). This is compatible with an HPV infectious cause of 
the cancer.
cOnclUsiOn
In this current study, there were four observations of particular 
interest: (i) confirmation by both NGS and a range of PCR 
techniques, of the presence of high-risk HPV gene sequences in 
breast cancers, (ii) there is a correlation between high-risk HPV 
gene sequences in benign breast biopsy specimens and subse-
quent HPV-positive breast cancer in the same patient, which is 
an indication of prior HPV infection before the development of 
HPV-positive breast cancer, (iii) that HPVs in breast cancer are 
likely to be biologically active (as shown by transcription of HPV 
DNA to RNA plus the expression of HPV E7 proteins), and (iv) 
that HPV oncogenic influences may occur early in the step by step 
development of breast cancer.
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